These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 20236088)
1. The patented uses of D-ribose in cardiovascular diseases. Shecterle LM; Terry KR; St Cyr JA Recent Pat Cardiovasc Drug Discov; 2010 Jun; 5(2):138-42. PubMed ID: 20236088 [TBL] [Abstract][Full Text] [Related]
2. D-ribose aids advanced ischemic heart failure patients. MacCarter D; Vijay N; Washam M; Shecterle L; Sierminski H; St Cyr JA Int J Cardiol; 2009 Sep; 137(1):79-80. PubMed ID: 18674831 [TBL] [Abstract][Full Text] [Related]
3. Ribose in the heart. Herrick J; St Cyr J J Diet Suppl; 2008; 5(2):213-7. PubMed ID: 22432434 [TBL] [Abstract][Full Text] [Related]
4. D-ribose, a metabolic substrate for congestive heart failure. Wagner S; Herrick J; Shecterle LM; St Cyr JA Prog Cardiovasc Nurs; 2009 Jun; 24(2):59-60. PubMed ID: 19523159 [TBL] [Abstract][Full Text] [Related]
5. The benefits of ribose in cardiovascular disease. Pauly DF; Johnson C; St Cyr JA Med Hypotheses; 2003 Feb; 60(2):149-51. PubMed ID: 12606226 [TBL] [Abstract][Full Text] [Related]
6. D-Ribose as a supplement for cardiac energy metabolism. Pauly DF; Pepine CJ J Cardiovasc Pharmacol Ther; 2000 Oct; 5(4):249-58. PubMed ID: 11150394 [TBL] [Abstract][Full Text] [Related]
7. Potential Clinical Benefits of D-ribose in Ischemic Cardiovascular Disease. Shecterle LM; Terry KR; St Cyr JA Cureus; 2018 Mar; 10(3):e2291. PubMed ID: 29750132 [TBL] [Abstract][Full Text] [Related]
8. A sugar that benefits failing hearts. St Cyr JA; Schneider JR Int J Cardiol; 2009 Jan; 131(3):398. PubMed ID: 17996314 [TBL] [Abstract][Full Text] [Related]
9. A sugar for congestive heart failure patients. Shecterle LM; Wagner S; St Cyr JA Ther Adv Cardiovasc Dis; 2011 Apr; 5(2):95-7. PubMed ID: 21310762 [No Abstract] [Full Text] [Related]
10. D-Ribose improves diastolic function and quality of life in congestive heart failure patients: a prospective feasibility study. Omran H; Illien S; MacCarter D; St Cyr J; Lüderitz B Eur J Heart Fail; 2003 Oct; 5(5):615-9. PubMed ID: 14607200 [TBL] [Abstract][Full Text] [Related]
11. Influence of ribose, adenosine, and "AICAR" on the rate of myocardial adenosine triphosphate synthesis during reperfusion after coronary artery occlusion in the dog. Mauser M; Hoffmeister HM; Nienaber C; Schaper W Circ Res; 1985 Feb; 56(2):220-30. PubMed ID: 3918804 [TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders. Henning RJ; Bourgeois M; Harbison RD Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072 [TBL] [Abstract][Full Text] [Related]
13. D-ribose benefits heart failure patients. Vijay N; MacCarter D; Shecterle LM; St Cyr JA J Med Food; 2008 Mar; 11(1):199-200. PubMed ID: 18361759 [No Abstract] [Full Text] [Related]
14. Preischemic administration of ribose to delay the onset of irreversible ischemic injury and improve function: studies in normal and hypertrophied hearts. Wallen WJ; Belanger MP; Wittnich C Can J Physiol Pharmacol; 2003 Jan; 81(1):40-7. PubMed ID: 12665256 [TBL] [Abstract][Full Text] [Related]
15. The heart metabolism: pathophysiological aspects in ischaemia and heart failure. Abozguia K; Shivu GN; Ahmed I; Phan TT; Frenneaux MP Curr Pharm Des; 2009; 15(8):827-35. PubMed ID: 19275646 [TBL] [Abstract][Full Text] [Related]
16. How to mediate cardioprotection in ischemic hearts--accumulated evidence of basic research should translate to clinical medicine. Kitakaze M Cardiovasc Drugs Ther; 2010 Jun; 24(3):217-23. PubMed ID: 20645124 [TBL] [Abstract][Full Text] [Related]
17. Cardiac P2X(4) receptors: targets in ischemia and heart failure? Yang R; Liang BT Circ Res; 2012 Aug; 111(4):397-401. PubMed ID: 22859669 [TBL] [Abstract][Full Text] [Related]